Lican Developments

Lican Developments is a clinical-stage biotechnology company dedicated to the development of novel therapies for lysosomal storage disorders, specifically Gaucher disease. The company's lead program, LC-001, is an oral small molecule substrate reduction therapy (SRT) that targets glucosylceramide synthase to prevent the buildup of harmful glycolipids. Founded by world-renowned Gaucher disease expert Prof. Ari Zimran, the company leverages specialized clinical insights to improve patient outcomes and quality of life. Lican Developments is currently advancing its pipeline through clinical trials to establish LC-001 as a primary or adjunctive treatment option for patients with various types of Gaucher disease.